Dermatologic Adverse Events of Cancer Therapy




Abstract


Over the last few decades, treatment of cancer has evolved to include therapies that may be broadly categorized as traditional cytotoxic chemotherapies, hormonal therapies, targeted therapies, and immunotherapies. From the dermatologic perspective, cytotoxic chemotherapies have long generated much interest because of the potential to cause alopecia, their hallmark adverse event (AE). The introduction of various targeted therapies and immunotherapies in recent years, however, has led to the recognition of a broad spectrum of dermatologic AEs. In this chapter, we provide an overview of the dermatologic AEs associated with major classes of cancer therapies, as well as the management options for common entities. Besides the physical and emotional impact, impairments in patients’ quality of life, and financial burden, these AEs may also disrupt cancer treatments. Therefore, their timely recognition and prompt management are crucial for optimal clinical outcomes.




Keywords

Antineoplastic agents, adverse events, Drug eruption, drug therapy, Epidermal growth factor–receptor inhibitors, Molecular molecularly targeted therapies

 





Key Points





  • Dermatologic adverse events (AEs) of cancer therapies can cause patient discomfort and impair their quality of life, increase the cost of medical care, and even result in dose modifications, all of which can negatively impact clinical outcomes.



  • The traditional cytotoxic chemotherapies are commonly associated with dermatologic AEs such as alopecia, hypersensitivity reactions, xerosis, skin hyperpigmentation, nail changes, and hand-foot syndrome (HFS).



  • Targeted therapies encompass drugs that inhibit selective molecules and pathways critical for carcinogenesis, tumor growth, and survival. The ensuing dermatologic AEs tend to vary depending on the entity targeted (e.g., epidermal growth factor receptor [EGFR], vascular endothelial growth factor/vascular endothelial growth factor receptor, immune checkpoints, mammalian target of rapamycin), although there is overlap.



  • Acneiform rash, xerosis, skin hyperpigmentation, alopecia, hair disorders (e.g. dyspigmentation, hypertrichosis, trichomegaly, textural changes), paronychia, and mucosal inflammation are characteristic dermatologic AEs of the EGFR inhibitors. Treatment with inhibitors of angiogenesis often leads to HFS, exanthems, hair disorders (alopecia, dyspigmentation, and textural changes), xerosis, mucositis, and in the case of bevacizumab/aflibercept, impairment of wound healing. The immune checkpoint inhibitors often result in pruritus and maculopapular cutaneous eruptions, although their AE profile, as with other newly developed drugs, is emerging and pending further characterization.



  • Timely recognition, prompt management of dermatologic AEs related to cancer treatment, and appropriate counseling are crucial for optimal clinical outcomes, and require a multidisciplinary approach involving oncologists, dermatologists, and nurses.





Introduction


Over the last few decades, treatment of cancer has evolved to include therapies that may be broadly categorized as traditional cytotoxic chemotherapies, hormonal therapies, targeted therapies, and immunotherapies ( Table 18-1 ). From the dermatologic perspective, cytotoxic chemotherapies have long generated much interest because of the potential to cause alopecia, their hallmark adverse event (AE). The introduction of various targeted therapies and immunotherapies in recent years, however, has led to the recognition of a broad spectrum of dermatologic AEs ( Table 18-2 ). Besides the physical and emotional impact, impairments in patients’ quality of life, and financial burden, these AEs may also disrupt cancer treatments. Therefore, their timely recognition and prompt management are crucial for optimal clinical outcomes.



TABLE 18-1

Overview of Drugs Currently Approved in the Treatment of Various Cancers





















Cytotoxic Chemotherapeutic Agents
Alkylating agents Nitrogen mustards Aziridines and epoxides Alkyl sulfonates Nitrosoureas Hydrazines and triazine derivatives
Mechlorethamine
Cyclophosphamide
Ifosfamide
Melphalan
Chlorambucil
ThioTEPA
Mitomycin-C
Busulfan Carmustine
Streptozocin
Procarbazine,
Dacarbazine
Temozolomide
Hydroxyurea









Antimetabolite agents Folate Antagonists
Methotrexate
Pemetrexed
Pyrimidine Analogs
5-Fluorouracil
Capecitabine
Cytarabine
Gemcitabine
Purine Analogs
Mercaptopurine
Thioguanine
Fludarabine
Cladribine








Topoisomerase-interacting agents Topoisomerase I inhibitors
Irinotecan, Topotecan
Topoisomerase II inhibitors
Anthracyclines
Etoposide, Tenoposide
Mitoxantrone









Antimicrotubule agents Taxanes
Paclitaxel
Docetaxel
Nab-paclitaxel
Vinca alkaloids
Vinblastine
Vincristine
Vinorelbine
Vindesine
Vinflunine

Estramustine phosphate sodium















Epigenetic modulators Histone deacetylase inhibitors
Vorinostat
Romidepsin
Proteasome inhibitors
Bortezomib
Carfilzomib
Demethylating agents
5-Azacitidine
Decitabine
Retinoids Bexarotene
All-trans retinoic acid
Arsenicals Arsenic trioxide











Targeted Anticancer Agents
EGFR inhibitors EGFR inhibitors
Erlotinib
Cetuximab
Panitumumab
Gefitinib
EGFR/HER2 inhibitors
Afatinib
Lapatinib
EGFR/VEGFR inhibitors
Vandetanib






































Angiogenesis inhibitors VEGF inhibitors
Bevacizumab
Aflibercept
VEGFR inhibitors
Sorafenib
Sunitinib
Pazopanib
Axitinib
Regorafenib
Cabozantinib
BRAF inhibitors Vemurafenib, Dabrafenib
BCR-ABL inhibitors Imatinib, Nilotinib, Dasatinib, Ponatinib, Bosutinib
mTOR inhibitors Everolimus, Temsirolimus
MEK inhibitors Trametinib
SMO inhibitors Vismodegib
JAK inhibitors Ruxolitinib
PI3K inhibitors Idelalisib
BTK inhibitors Ibrutinib
ALK inhibitors Crizotinib
Immune checkpoint inhibitors Ipilimumab, Nivolumab, Pembrolizumab










Other monoclonal antibodies HER-2
Trastuzumab
Ado-trastuzumab emtansine
Pertuzumab
CD20
Rituximab
Ofatumumab
Obinutuzumab
CD30
Brentuximab
CD-52
Alemtuzumab

























Other Anticancer Agents
Endocrine agents SERMs ERDs Aromatase inhibitors LHRH agonists Androgens Antiandrogens Somatostatin analogs
Tamoxifen
Toremifene
Raloxifene
Fulvestrant Exemestane
Anastrozole
Letrozole
Leuprolide Fluoxy-mesterone Flutamide
Bicalutamide
Megestrol acetate Octreotide acetate











Miscellaneous

l -Asparaginase

Bleomycin
Thalidomides
Thalidomide
Lenalidomide
Pomalidomide

EGFR, epidermal growth factor receptor; HER, human epidermal growth factor receptor; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor; BRAF, B-rapidly accelerated fibrosarcoma; BCR-abl, breakpoint cluster region-abelson; mTOR, mechanistic target of rapamycin; MEK, MAPK/ERK (extracellular signal-regulated kinase) Kinase; SMO, smoothened; JAK, janus kinase; Pi3K, phosphoinositide 3-kinase; BTK, Bruton’s tyrosine kinase; ALK, anaplastic lymphoma kinase; CD, cluster of differentiation; SERMs, selective estrogen receptor modulators; ERDs, estrogen receptor downregulators; LHRH, luteinizing hormone-releasing hormone.


TABLE 18-2

Common and Clinically Significant Dermatologic Adverse Events from Targeted Anticancer Agents






























































































































































































































































































































































































































Primary Molecular Target EGFR Multikinase VEGF VEGFR/PDGFR BRAF mTOR/PI3K CD20 HER-2 CTLA-4 PD-1
Anticancer
agents


Cetuximab, Panitumumab, Erlotinib, Afatinib, Lapatinib Imatinib (I), Nilotinib (N), Dasatinib (D) Bevacizumab (B), Aflibercept (A) Sorafenib (So), Sunitinib (Su), Pazopanib (P), Axitinib (Ax), Regorafenib (R), Cabozantinib (C) Vemurafenib, Dabrafenib Everolimus (E), Temsirolimus (T), Idelalisib (I) Rituximab, Ibritumomab tiuxetan Trastuzumab (Tr), Trastuzumab emtansine (T-DM1) Ipilimumab Nivolumab (Nv), Pembrolizumab (P)
Dermatologic
adverse event
Skin
Cutaneous eruptions +++ +++ (B) ++ ++ +++ (E, T) ++ (I) + (Tr) +++ +++
Maculopapular
Papulopustular (“acneiform”) +++ +++ (E, T) + (Nv)
Keratosis pilaris-like + ++
Xerosis ++ ++ ++ ++ ++ (E, T)
Fissures (fingertips, toes) ++
Skin infections (Bacterial, viral, fungal) + +
Pruritus ++ ++ ++ (B) ++ + +++ (E, T) +++ +++
Hand-foot skin reaction + +++ + +++ (T-DM1)
Photosensitivity +++ + + +++ + (Nv)
Pigmentary changes + + (A)
Hyperpigmentation
Hypopigmentation + (I) + (Su)
Depigmentation (vitiligo) ++ (I) ++ +
Impaired wound healing + +++
Skin neoplasms (KA/cuSCC) + (So, R) +++
Psoriasis exacerbation or psoriasiform eruptions ++ (I)
Lichenoid eruptions + (I)
Eruptive nevi + (So)
Facial edema +++ ++ (Su)
Appendages
Hair ++ + + ++ (So, Su); + (P) ++ ++ (Tr) +
Alopecia
Hypertrichosis, trichomegaly +++
Curling ++ ++ ++
Hyperpigmentation + (P)
Hypopigmentation + + (Su); ++ (P) + (P)
Nail ++ ++ (E, T)
Paronychia
Nail abnormalities ++ ++
MUCOSAE ++ ++ + + +++ (E, T)
Mucositis, stomatitis
Bleeding, hemorrhages + (B)
Cutaneous and mucosal telangiectasia + +++ (T-DM1)
Geographic tongue + (B)
Mucocutaneous reactions +

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Sep 15, 2019 | Posted by in Dermatology | Comments Off on Dermatologic Adverse Events of Cancer Therapy

Full access? Get Clinical Tree

Get Clinical Tree app for offline access